Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2000 Jun;84(6):654–666. doi: 10.1136/bjo.84.6.654

Matrix metalloproteinase biology applied to vitreoretinal disorders

C SETHI 1, T BAILEY 1, P LUTHERT 1, N CHONG 1
PMCID: PMC1723500  PMID: 10837397

Full Text

The Full Text of this article is available as a PDF (174.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi Y., Itoh F., Yamamoto H., Matsuno K., Arimura Y., Kusano M., Endoh T., Hinoda Y., Oohara M., Hosokawa M. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. Int J Oncol. 1998 Nov;13(5):1031–1035. doi: 10.3892/ijo.13.5.1031. [DOI] [PubMed] [Google Scholar]
  2. Adelberg D. A., Del Priore L. V., Kaplan H. J. Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina. 1995;15(3):198–205. doi: 10.1097/00006982-199515030-00003. [DOI] [PubMed] [Google Scholar]
  3. Ahmad A., Hanby A., Dublin E., Poulsom R., Smith P., Barnes D., Rubens R., Anglard P., Hart I. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol. 1998 Mar;152(3):721–728. [PMC free article] [PubMed] [Google Scholar]
  4. Alexander J. P., Bradley J. M., Gabourel J. D., Acott T. S. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1990 Dec;31(12):2520–2528. [PubMed] [Google Scholar]
  5. Ali R. R., Reichel M. B., Hunt D. M., Bhattacharya S. S. Gene therapy for inherited retinal degeneration. Br J Ophthalmol. 1997 Sep;81(9):795–801. doi: 10.1136/bjo.81.9.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Anand-Apte B., Bao L., Smith R., Iwata K., Olsen B. R., Zetter B., Apte S. S. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 1996;74(6):853–862. doi: 10.1139/o96-090. [DOI] [PubMed] [Google Scholar]
  7. Anand-Apte B., Pepper M. S., Voest E., Montesano R., Olsen B., Murphy G., Apte S. S., Zetter B. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci. 1997 Apr;38(5):817–823. [PubMed] [Google Scholar]
  8. Andersen K., Maelandsmo G. M., Hovig E., Fodstad O., Loennechen T., Winberg J. O. Interleukin-1 alpha and basic fibroblast growth factor induction of matrix metalloproteinases and their inhibitors in osteosarcoma cells is modulated by the metastasis associated protein CAPL. Anticancer Res. 1998 Sep-Oct;18(5A):3299–3303. [PubMed] [Google Scholar]
  9. Apte S. S., Mattei M. G., Olsen B. R. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics. 1994 Jan 1;19(1):86–90. doi: 10.1006/geno.1994.1016. [DOI] [PubMed] [Google Scholar]
  10. Arumugam S., Jang Y. C., Chen-Jensen C., Gibran N. S., Isik F. F. Temporal activity of plasminogen activators and matrix metalloproteinases during cutaneous wound repair. Surgery. 1999 Jun;125(6):587–593. [PubMed] [Google Scholar]
  11. Ashley R. A. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann N Y Acad Sci. 1999 Jun 30;878:335–346. doi: 10.1111/j.1749-6632.1999.tb07693.x. [DOI] [PubMed] [Google Scholar]
  12. Baramova E., Foidart J. M. Matrix metalloproteinase family. Cell Biol Int. 1995 Mar;19(3):239–242. [PubMed] [Google Scholar]
  13. Bird A. Age-related macular disease. Br J Ophthalmol. 1996 Jan;80(1):2–3. doi: 10.1136/bjo.80.1.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F., Castner B. J., Stocking K. L., Reddy P., Srinivasan S. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997 Feb 20;385(6618):729–733. doi: 10.1038/385729a0. [DOI] [PubMed] [Google Scholar]
  15. Blavier L., Henriet P., Imren S., Declerck Y. A. Tissue inhibitors of matrix metalloproteinases in cancer. Ann N Y Acad Sci. 1999 Jun 30;878:108–119. doi: 10.1111/j.1749-6632.1999.tb07677.x. [DOI] [PubMed] [Google Scholar]
  16. Bond M., Fabunmi R. P., Baker A. H., Newby A. C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998 Sep 11;435(1):29–34. doi: 10.1016/s0014-5793(98)01034-5. [DOI] [PubMed] [Google Scholar]
  17. Bramhall S. R., Neoptolemos J. P., Stamp G. W., Lemoine N. R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol. 1997 Jul;182(3):347–355. doi: 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  18. Bramhall S. R. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol. 1997 Feb;21(1):1–12. doi: 10.1007/BF02785914. [DOI] [PubMed] [Google Scholar]
  19. Bressler N. M., Bressler S. B., Fine S. L. Age-related macular degeneration. Surv Ophthalmol. 1988 May-Jun;32(6):375–413. doi: 10.1016/0039-6257(88)90052-5. [DOI] [PubMed] [Google Scholar]
  20. Brooks P. C., Silletti S., von Schalscha T. L., Friedlander M., Cheresh D. A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998 Feb 6;92(3):391–400. doi: 10.1016/s0092-8674(00)80931-9. [DOI] [PubMed] [Google Scholar]
  21. Brown P. D. Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999 Jan;107(1):174–180. doi: 10.1111/j.1699-0463.1999.tb01541.x. [DOI] [PubMed] [Google Scholar]
  22. Brown P. D. Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999 Jan;107(1):174–180. doi: 10.1111/j.1699-0463.1999.tb01541.x. [DOI] [PubMed] [Google Scholar]
  23. Brown P. D. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol. 1997 Mar;14(1):1–10. doi: 10.1007/BF02990939. [DOI] [PubMed] [Google Scholar]
  24. Brown P. D. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat. 1998;52(1-3):125–136. doi: 10.1023/a:1006119319695. [DOI] [PubMed] [Google Scholar]
  25. Cawston T. E., Billington C. Metalloproteinases in the rheumatic diseases. J Pathol. 1996 Oct;180(2):115–117. doi: 10.1002/(SICI)1096-9896(199610)180:2<115::AID-PATH674>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  26. Charteris D. G. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995 Oct;79(10):953–960. doi: 10.1136/bjo.79.10.953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Chong N. H., Alexander R. A., Gin T., Bird A. C., Luthert P. J. TIMP-3, collagen, and elastin immunohistochemistry and histopathology of Sorsby's fundus dystrophy. Invest Ophthalmol Vis Sci. 2000 Mar;41(3):898–902. [PubMed] [Google Scholar]
  28. Clark A. F. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2514–2516. [PubMed] [Google Scholar]
  29. Cockett M. I., Murphy G., Birch M. L., O'Connell J. P., Crabbe T., Millican A. T., Hart I. R., Docherty A. J. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp. 1998;63:295–313. [PubMed] [Google Scholar]
  30. Connor T. B., Jr, Roberts A. B., Sporn M. B., Danielpour D., Dart L. L., Michels R. G., de Bustros S., Enger C., Kato H., Lansing M. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989 May;83(5):1661–1666. doi: 10.1172/JCI114065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Crawford H. C., Matrisian L. M. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein. 1996;49(1-3):20–37. doi: 10.1159/000468614. [DOI] [PubMed] [Google Scholar]
  32. Das A., McGuire P. G., Eriqat C., Ober R. R., DeJuan E., Jr, Williams G. A., McLamore A., Biswas J., Johnson D. W. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):809–813. [PubMed] [Google Scholar]
  33. Das A., McLamore A., Song W., McGuire P. G. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999 Apr;117(4):498–503. doi: 10.1001/archopht.117.4.498. [DOI] [PubMed] [Google Scholar]
  34. De La Paz M. A., Itoh Y., Toth C. A., Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1256–1260. [PubMed] [Google Scholar]
  35. De La Paz M. A., Pericak-Vance M. A., Lennon F., Haines J. L., Seddon J. M. Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997 May;38(6):1060–1065. [PubMed] [Google Scholar]
  36. DeClerck Y. A., Perez N., Shimada H., Boone T. C., Langley K. E., Taylor S. M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992 Feb 1;52(3):701–708. [PubMed] [Google Scholar]
  37. Di Colandrea T., Wang L., Wille J., D'Armiento J., Chada K. K. Epidermal expression of collagenase delays wound-healing in transgenic mice. J Invest Dermatol. 1998 Dec;111(6):1029–1033. doi: 10.1046/j.1523-1747.1998.00457.x. [DOI] [PubMed] [Google Scholar]
  38. Ebihara I., Nakamura T., Shimada N., Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998 Oct;32(4):544–550. doi: 10.1016/s0272-6386(98)70015-0. [DOI] [PubMed] [Google Scholar]
  39. Edwards D. R., Murphy G., Reynolds J. J., Whitham S. E., Docherty A. J., Angel P., Heath J. K. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987 Jul;6(7):1899–1904. doi: 10.1002/j.1460-2075.1987.tb02449.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Fariss R. N., Apte S. S., Luthert P. J., Bird A. C., Milam A. H. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol. 1998 Nov;82(11):1329–1334. doi: 10.1136/bjo.82.11.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Fariss R. N., Apte S. S., Olsen B. R., Iwata K., Milam A. H. Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am J Pathol. 1997 Jan;150(1):323–328. [PMC free article] [PubMed] [Google Scholar]
  42. Felbor U., Doepner D., Schneider U., Zrenner E., Weber B. H. Evaluation of the gene encoding the tissue inhibitor of metalloproteinases-3 in various maculopathies. Invest Ophthalmol Vis Sci. 1997 May;38(6):1054–1059. [PubMed] [Google Scholar]
  43. Felbor U., Stöhr H., Amann T., Schönherr U., Apfelstedt-Sylla E., Weber B. H. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy. J Med Genet. 1996 Mar;33(3):233–236. doi: 10.1136/jmg.33.3.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Fingleton B. M., Heppner Goss K. J., Crawford H. C., Matrisian L. M. Matrilysin in early stage intestinal tumorigenesis. APMIS. 1999 Jan;107(1):102–110. doi: 10.1111/j.1699-0463.1999.tb01532.x. [DOI] [PubMed] [Google Scholar]
  45. Fortunato S. J., Menon R., Lombardi S. J. Presence of four tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -3 and -4) in human fetal membranes. Am J Reprod Immunol. 1998 Dec;40(6):395–400. doi: 10.1111/j.1600-0897.1998.tb00424.x. [DOI] [PubMed] [Google Scholar]
  46. Fowlkes J. L., Serra D. M., Nagase H., Thrailkill K. M. MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth. Ann N Y Acad Sci. 1999 Jun 30;878:696–699. doi: 10.1111/j.1749-6632.1999.tb07765.x. [DOI] [PubMed] [Google Scholar]
  47. Fukuda Y., Ishizaki M., Kudoh S., Kitaichi M., Yamanaka N. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest. 1998 Jun;78(6):687–698. [PubMed] [Google Scholar]
  48. Garzetti G. G., Ciavattini A., Lucarini G., Pugnaloni A., De Nictolis M., Amati S., Romanini C., Biagini G. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer. 1999 May 15;85(10):2219–2225. doi: 10.1002/(sici)1097-0142(19990515)85:10<2219::aid-cncr17>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  49. Gomez D. E., Alonso D. F., Yoshiji H., Thorgeirsson U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997 Oct;74(2):111–122. [PubMed] [Google Scholar]
  50. Gomis-Rüth F. X., Maskos K., Betz M., Bergner A., Huber R., Suzuki K., Yoshida N., Nagase H., Brew K., Bourenkov G. P. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997 Sep 4;389(6646):77–81. doi: 10.1038/37995. [DOI] [PubMed] [Google Scholar]
  51. Grant M. B., Caballero S., Tarnuzzer R. W., Bass K. E., Ljubimov A. V., Spoerri P. E., Galardy R. E. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes. 1998 Aug;47(8):1311–1317. doi: 10.2337/diab.47.8.1311. [DOI] [PubMed] [Google Scholar]
  52. Guo L., Hussain A. A., Limb G. A., Marshall J. Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2676–2682. [PubMed] [Google Scholar]
  53. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994 Sep;107(Pt 9):2373–2379. doi: 10.1242/jcs.107.9.2373. [DOI] [PubMed] [Google Scholar]
  54. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E., Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992 Feb 17;298(1):29–32. doi: 10.1016/0014-5793(92)80015-9. [DOI] [PubMed] [Google Scholar]
  55. Hee M. R., Baumal C. R., Puliafito C. A., Duker J. S., Reichel E., Wilkins J. R., Coker J. G., Schuman J. S., Swanson E. A., Fujimoto J. G. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996 Aug;103(8):1260–1270. doi: 10.1016/s0161-6420(96)30512-5. [DOI] [PubMed] [Google Scholar]
  56. Heller R. A., Schena M., Chai A., Shalon D., Bedilion T., Gilmore J., Woolley D. E., Davis R. W. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2150–2155. doi: 10.1073/pnas.94.6.2150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Hembry R. M., Ehrlich H. P. Immunolocalization of collagenase and tissue inhibitor of metalloproteinases (TIMP) in hypertrophic scar tissue. Br J Dermatol. 1986 Oct;115(4):409–420. doi: 10.1111/j.1365-2133.1986.tb06235.x. [DOI] [PubMed] [Google Scholar]
  58. Henriet P., Blavier L., Declerck Y. A. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS. 1999 Jan;107(1):111–119. doi: 10.1111/j.1699-0463.1999.tb01533.x. [DOI] [PubMed] [Google Scholar]
  59. Hiraoka N., Allen E., Apel I. J., Gyetko M. R., Weiss S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998 Oct 30;95(3):365–377. doi: 10.1016/s0092-8674(00)81768-7. [DOI] [PubMed] [Google Scholar]
  60. Ho A. C., Maguire M. G., Yoken J., Lee M. S., Shin D. S., Javornik N. B., Fine S. L. Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology. 1999 Jul;106(7):1367–1374. doi: 10.1016/s0161-6420(99)00735-6. [DOI] [PubMed] [Google Scholar]
  61. Hua J., Muschel R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 1996 Nov 15;56(22):5279–5284. [PubMed] [Google Scholar]
  62. Hunt R. C., Fox A., al Pakalnis V., Sigel M. M., Kosnosky W., Choudhury P., Black E. P. Cytokines cause cultured retinal pigment epithelial cells to secrete metalloproteinases and to contract collagen gels. Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3179–3186. [PubMed] [Google Scholar]
  63. Ignotz R. A., Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986 Mar 25;261(9):4337–4345. [PubMed] [Google Scholar]
  64. Imai K., Hiramatsu A., Fukushima D., Pierschbacher M. D., Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 1997 Mar 15;322(Pt 3):809–814. doi: 10.1042/bj3220809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Immonen I., Konttinen Y. T., Sorsa T., Tommila P., Sirén V. Proteinases in subretinal fluid. Graefes Arch Clin Exp Ophthalmol. 1996 Feb;234(2):105–109. doi: 10.1007/BF00695249. [DOI] [PubMed] [Google Scholar]
  66. Jacobson S. G., Cideciyan A. V., Regunath G., Rodriguez F. J., Vandenburgh K., Sheffield V. C., Stone E. M. Night blindness in Sorsby's fundus dystrophy reversed by vitamin A. Nat Genet. 1995 Sep;11(1):27–32. doi: 10.1038/ng0995-27. [DOI] [PubMed] [Google Scholar]
  67. Johnatty R. N., Taub D. D., Reeder S. P., Turcovski-Corrales S. M., Cottam D. W., Stephenson T. J., Rees R. C. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol. 1997 Mar 1;158(5):2327–2333. [PubMed] [Google Scholar]
  68. Kadonosono K., Yazama F., Itoh N., Sawada H., Ohno S. Expression of matrix metalloproteinase-7 in choroidal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1999 Sep;128(3):382–384. doi: 10.1016/s0002-9394(99)00135-x. [DOI] [PubMed] [Google Scholar]
  69. Kamei M., Hollyfield J. G. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2367–2375. [PubMed] [Google Scholar]
  70. Kanbe N., Tanaka A., Kanbe M., Itakura A., Kurosawa M., Matsuda H. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol. 1999 Aug;29(8):2645–2649. doi: 10.1002/(SICI)1521-4141(199908)29:08<2645::AID-IMMU2645>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  71. Kawashima Y., Saika S., Yamanaka O., Okada Y., Ohkawa K., Ohnishi Y. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues. Curr Eye Res. 1998 Apr;17(4):445–451. doi: 10.1080/02713689808951226. [DOI] [PubMed] [Google Scholar]
  72. Kieseier B. C., Seifert T., Giovannoni G., Hartung H. P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology. 1999 Jul 13;53(1):20–25. doi: 10.1212/wnl.53.1.20. [DOI] [PubMed] [Google Scholar]
  73. Kleiner D. E., Jr, Stetler-Stevenson W. G. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol. 1993 Oct;5(5):891–897. doi: 10.1016/0955-0674(93)90040-w. [DOI] [PubMed] [Google Scholar]
  74. Kolb S. A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H. W., Fontana A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol. 1998 Apr 15;84(2):143–150. doi: 10.1016/s0165-5728(97)00247-6. [DOI] [PubMed] [Google Scholar]
  75. Kon C. H., Occleston N. L., Charteris D., Daniels J., Aylward G. W., Khaw P. T. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1524–1529. [PubMed] [Google Scholar]
  76. Kosano H., Okano T., Katsura Y., Noritake M., Kado S., Matsuoka T., Nishigori H. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. 1999;64(25):2307–2315. doi: 10.1016/s0024-3205(99)00184-8. [DOI] [PubMed] [Google Scholar]
  77. Kosnosky W., Li T. H., Pakalnis V. A., Fox A., Hunt R. C. Interleukin-1-beta changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes containing preexisting retinal holes. Invest Ophthalmol Vis Sci. 1994 Dec;35(13):4260–4267. [PubMed] [Google Scholar]
  78. Kossakowska A. E., Edwards D. R., Lee S. S., Urbanski L. S., Stabbler A. L., Zhang C. L., Phillips B. W., Zhang Y., Urbanski S. J. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol. 1998 Dec;153(6):1895–1902. doi: 10.1016/S0002-9440(10)65703-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Krüger A., Sanchez-Sweatman O. H., Martin D. C., Fata J. E., Ho A. T., Orr F. W., Rüther U., Khokha R. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene. 1998 May 7;16(18):2419–2423. doi: 10.1038/sj.onc.1201774. [DOI] [PubMed] [Google Scholar]
  80. Kumar R., Yoneda J., Bucana C. D., Fidler I. J. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol. 1998 Apr;12(4):749–757. doi: 10.3892/ijo.12.4.749. [DOI] [PubMed] [Google Scholar]
  81. Kähäri V. M., Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999 Feb;31(1):34–45. doi: 10.3109/07853899909019260. [DOI] [PubMed] [Google Scholar]
  82. Kähäri V. M., Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol. 1997 Oct;6(5):199–213. doi: 10.1111/j.1600-0625.1997.tb00164.x. [DOI] [PubMed] [Google Scholar]
  83. Langton K. P., Barker M. D., McKie N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation. J Biol Chem. 1998 Jul 3;273(27):16778–16781. doi: 10.1074/jbc.273.27.16778. [DOI] [PubMed] [Google Scholar]
  84. Leco K. J., Khokha R., Pavloff N., Hawkes S. P., Edwards D. R. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994 Mar 25;269(12):9352–9360. [PubMed] [Google Scholar]
  85. Lee K. S., Rha S. Y., Kim S. J., Kim J. H., Roh J. K., Kim B. S., Chung H. C. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis. 1996 Nov;14(6):512–519. doi: 10.1007/BF00115111. [DOI] [PubMed] [Google Scholar]
  86. Lein M., Nowak L., Jung K., Koenig F., Lichtinghagen R., Schnorr D., Loening S. A. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem. 1997 Aug;30(6):491–496. doi: 10.1016/s0009-9120(97)00097-0. [DOI] [PubMed] [Google Scholar]
  87. Levi E., Fridman R., Miao H. Q., Ma Y. S., Yayon A., Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7069–7074. doi: 10.1073/pnas.93.14.7069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Li Y. Y., McTiernan C. F., Feldman A. M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res. 1999 Apr;42(1):162–172. doi: 10.1016/s0008-6363(98)00297-1. [DOI] [PubMed] [Google Scholar]
  89. Limb A. S., Miller K., Chignell A. H., Williamson T. H., Hollifield R. D., Dumonde D. C. Metalloproteinases and TIMP-1 in proliferative vitreoretinopathy. Biochem Soc Trans. 1997 May;25(2):234S–234S. doi: 10.1042/bst025234s. [DOI] [PubMed] [Google Scholar]
  90. Lokeshwar B. L. MMP inhibition in prostate cancer. Ann N Y Acad Sci. 1999 Jun 30;878:271–289. doi: 10.1111/j.1749-6632.1999.tb07690.x. [DOI] [PubMed] [Google Scholar]
  91. Massova I., Kotra L. P., Fridman R., Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998 Sep;12(12):1075–1095. [PubMed] [Google Scholar]
  92. Matrisian L. M., Ganser G. L., Kerr L. D., Pelton R. W., Wood L. D. Negative regulation of gene expression by TGF-beta. Mol Reprod Dev. 1992 Jun;32(2):111–120. doi: 10.1002/mrd.1080320206. [DOI] [PubMed] [Google Scholar]
  93. Matrisian L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990 Apr;6(4):121–125. doi: 10.1016/0168-9525(90)90126-q. [DOI] [PubMed] [Google Scholar]
  94. Matsuo T., Okada Y., Shiraga F., Yanagawa T. TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. Jpn J Ophthalmol. 1998 Sep-Oct;42(5):377–380. doi: 10.1016/s0021-5155(98)00038-0. [DOI] [PubMed] [Google Scholar]
  95. Mattila L., Airola K., Ahonen M., Hietarinta M., Black C., Saarialho-Kere U., Kähäri V. M. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol. 1998 Apr;110(4):416–421. doi: 10.1046/j.1523-1747.1998.00138.x. [DOI] [PubMed] [Google Scholar]
  96. McGeehan G. M., Becherer J. D., Bast R. C., Jr, Boyer C. M., Champion B., Connolly K. M., Conway J. G., Furdon P., Karp S., Kidao S. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994 Aug 18;370(6490):558–561. doi: 10.1038/370558a0. [DOI] [PubMed] [Google Scholar]
  97. McLennan S. V., Death A. K., Fisher E. J., Williams P. F., Yue D. K., Turtle J. R. The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. Cell Mol Biol (Noisy-le-grand) 1999 Feb;45(1):123–135. [PubMed] [Google Scholar]
  98. Mooy C. M., De Jong P. T. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996 Nov-Dec;41(3):215–228. doi: 10.1016/s0039-6257(96)80024-5. [DOI] [PubMed] [Google Scholar]
  99. Morimoto Y., Nishikawa K., Ohashi M. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci. 1997;61(8):795–803. doi: 10.1016/s0024-3205(97)00561-4. [DOI] [PubMed] [Google Scholar]
  100. Moses M. A., Marikovsky M., Harper J. W., Vogt P., Eriksson E., Klagsbrun M., Langer R. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem. 1996 Mar 1;60(3):379–386. doi: 10.1002/(SICI)1097-4644(19960301)60:3%3C379::AID-JCB9%3E3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  101. Moses M. A. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15(3):180–189. doi: 10.1002/stem.150180. [DOI] [PubMed] [Google Scholar]
  102. Moss M. L., Jin S. L., Milla M. E., Bickett D. M., Burkhart W., Carter H. L., Chen W. J., Clay W. C., Didsbury J. R., Hassler D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997 Feb 20;385(6618):733–736. doi: 10.1038/385733a0. [DOI] [PubMed] [Google Scholar]
  103. Mueller B. M. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol. 1996;213(Pt 1):65–80. doi: 10.1007/978-3-642-61107-0_5. [DOI] [PubMed] [Google Scholar]
  104. Mun-Bryce S., Rosenberg G. A. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol. 1998 May;274(5 Pt 2):R1203–R1211. doi: 10.1152/ajpregu.1998.274.5.R1203. [DOI] [PubMed] [Google Scholar]
  105. Murate T., Yamashita K., Isogai C., Suzuki H., Ichihara M., Hatano S., Nakahara Y., Kinoshita T., Nagasaka T., Yoshida S. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol. 1997 Oct;99(1):181–189. doi: 10.1046/j.1365-2141.1997.3293146.x. [DOI] [PubMed] [Google Scholar]
  106. Murphy A. N., Unsworth E. J., Stetler-Stevenson W. G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol. 1993 Nov;157(2):351–358. doi: 10.1002/jcp.1041570219. [DOI] [PubMed] [Google Scholar]
  107. Murphy G., Docherty A. J., Hembry R. M., Reynolds J. J. Metalloproteinases and tissue damage. Br J Rheumatol. 1991;30 (Suppl 1):25–31. [PubMed] [Google Scholar]
  108. Murphy G., Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol. 1999 Oct;11(5):614–621. doi: 10.1016/s0955-0674(99)00022-8. [DOI] [PubMed] [Google Scholar]
  109. Murphy G., Knäuper V., Cowell S., Hembry R., Stanton H., Butler G., Freije J., Pendás A. M., López-Otín C. Evaluation of some newer matrix metalloproteinases. Ann N Y Acad Sci. 1999 Jun 30;878:25–39. doi: 10.1111/j.1749-6632.1999.tb07672.x. [DOI] [PubMed] [Google Scholar]
  110. Murphy G., Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol. 1997 Mar;15(8-9):511–518. doi: 10.1016/s0945-053x(97)90025-1. [DOI] [PubMed] [Google Scholar]
  111. Murphy G. The regulation of connective tissue metalloproteinases by natural inhibitors. Agents Actions Suppl. 1991;35:69–76. [PubMed] [Google Scholar]
  112. Murphy G., Ward R., Gavrilovic J., Atkinson S. Physiological mechanisms for metalloproteinase activation. Matrix Suppl. 1992;1:224–230. [PubMed] [Google Scholar]
  113. Norman J. T., Clark I. M., Garcia P. L. Regulation of TIMP-1 expression by hypoxia in kidney fibroblasts. Ann N Y Acad Sci. 1999 Jun 30;878:503–505. doi: 10.1111/j.1749-6632.1999.tb07709.x. [DOI] [PubMed] [Google Scholar]
  114. Nwomeh B. C., Liang H. X., Cohen I. K., Yager D. R. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res. 1999 Feb;81(2):189–195. doi: 10.1006/jsre.1998.5495. [DOI] [PubMed] [Google Scholar]
  115. Ormerod L. D., Puklin J. E., Frank R. N. Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. Ophthalmology. 1994 Jul;101(7):1201–1210. doi: 10.1016/s0161-6420(94)31200-0. [DOI] [PubMed] [Google Scholar]
  116. Overall C. M. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann N Y Acad Sci. 1994 Sep 6;732:51–64. doi: 10.1111/j.1749-6632.1994.tb24724.x. [DOI] [PubMed] [Google Scholar]
  117. Padgett L. C., Lui G. M., Werb Z., LaVail M. M. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation. Exp Eye Res. 1997 Jun;64(6):927–938. doi: 10.1006/exer.1997.0287. [DOI] [PubMed] [Google Scholar]
  118. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem. 1999 Mar 26;274(13):8925–8932. doi: 10.1074/jbc.274.13.8925. [DOI] [PubMed] [Google Scholar]
  119. Peng K. W., Morling F. J., Cosset F. L., Murphy G., Russell S. J. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther. 1997 Apr 10;8(6):729–738. doi: 10.1089/hum.1997.8.6-729. [DOI] [PubMed] [Google Scholar]
  120. Pilcher B. K., Wang M., Qin X. J., Parks W. C., Senior R. M., Welgus H. G. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann N Y Acad Sci. 1999 Jun 30;878:12–24. doi: 10.1111/j.1749-6632.1999.tb07671.x. [DOI] [PubMed] [Google Scholar]
  121. Plantner J. J., Jiang C., Smine A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res. 1998 Dec;67(6):637–645. doi: 10.1006/exer.1998.0552. [DOI] [PubMed] [Google Scholar]
  122. Plantner J. J., Smine A., Quinn T. A. Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous. Curr Eye Res. 1998 Feb;17(2):132–140. doi: 10.1076/ceyr.17.2.132.5610. [DOI] [PubMed] [Google Scholar]
  123. Rasmussen H. S., McCann P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69–75. doi: 10.1016/s0163-7258(97)00023-5. [DOI] [PubMed] [Google Scholar]
  124. Rifkin D. B., Mazzieri R., Munger J. S., Noguera I., Sung J. Proteolytic control of growth factor availability. APMIS. 1999 Jan;107(1):80–85. doi: 10.1111/j.1699-0463.1999.tb01529.x. [DOI] [PubMed] [Google Scholar]
  125. Ring P., Johansson K., Höyhtyä M., Rubin K., Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage. Br J Cancer. 1997;76(6):805–811. doi: 10.1038/bjc.1997.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Ryan M. E., Ramamurthy N. S., Sorsa T., Golub L. M. MMP-mediated events in diabetes. Ann N Y Acad Sci. 1999 Jun 30;878:311–334. doi: 10.1111/j.1749-6632.1999.tb07692.x. [DOI] [PubMed] [Google Scholar]
  127. SORSBY A., MASON M. E. J. A fundus dystrophy with unusual features. Br J Ophthalmol. 1949 Feb;33(2):67–97. doi: 10.1136/bjo.33.2.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Salo T., Mäkelä M., Kylmäniemi M., Autio-Harmainen H., Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest. 1994 Feb;70(2):176–182. [PubMed] [Google Scholar]
  129. Sang Q. X. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998 Sep;8(3):171–177. doi: 10.1038/cr.1998.17. [DOI] [PubMed] [Google Scholar]
  130. Sawicki G., Sanders E. J., Salas E., Wozniak M., Rodrigo J., Radomski M. W. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost. 1998 Nov;80(5):836–839. [PubMed] [Google Scholar]
  131. Schönbeck U., Mach F., Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998 Oct 1;161(7):3340–3346. [PubMed] [Google Scholar]
  132. Scott K. A., Wood E. J., Karran E. H. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett. 1998 Dec 11;441(1):137–140. doi: 10.1016/s0014-5793(98)01542-7. [DOI] [PubMed] [Google Scholar]
  133. Seiki M. Membrane-type matrix metalloproteinases. APMIS. 1999 Jan;107(1):137–143. doi: 10.1111/j.1699-0463.1999.tb01536.x. [DOI] [PubMed] [Google Scholar]
  134. Shalinsky D. R., Brekken J., Zou H., McDermott C. D., Forsyth P., Edwards D., Margosiak S., Bender S., Truitt G., Wood A. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999 Jun 30;878:236–270. doi: 10.1111/j.1749-6632.1999.tb07689.x. [DOI] [PubMed] [Google Scholar]
  135. Shapiro S. D., Campbell E. J., Kobayashi D. K., Welgus H. G. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J Clin Invest. 1990 Oct;86(4):1204–1210. doi: 10.1172/JCI114826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Shapiro S. D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998 Oct;10(5):602–608. doi: 10.1016/s0955-0674(98)80035-5. [DOI] [PubMed] [Google Scholar]
  137. Shapiro S. D. Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function. Matrix Biol. 1997 Mar;15(8-9):527–533. doi: 10.1016/s0945-053x(97)90027-5. [DOI] [PubMed] [Google Scholar]
  138. Smine A., Plantner J. J. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res. 1997 Sep;16(9):925–929. doi: 10.1076/ceyr.16.9.925.5044. [DOI] [PubMed] [Google Scholar]
  139. Sorsa T., Mäntylä P., Rönkä H., Kallio P., Kallis G. B., Lundqvist C., Kinane D. F., Salo T., Golub L. M., Teronen O. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann N Y Acad Sci. 1999 Jun 30;878:130–140. doi: 10.1111/j.1749-6632.1999.tb07679.x. [DOI] [PubMed] [Google Scholar]
  140. Spirin K. S., Ljubimov A. V., Castellon R., Wiedoeft O., Marano M., Sheppard D., Kenney M. C., Brown D. J. Analysis of gene expression in human bullous keratopathy corneas containing limiting amounts of RNA. Invest Ophthalmol Vis Sci. 1999 Dec;40(13):3108–3115. [PubMed] [Google Scholar]
  141. Steen B., Sejersen S., Berglin L., Seregard S., Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998 Oct;39(11):2194–2200. [PubMed] [Google Scholar]
  142. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol. 1999 Oct;11(5):634–640. doi: 10.1016/s0955-0674(99)00026-5. [DOI] [PubMed] [Google Scholar]
  143. Stüve O., Dooley N. P., Uhm J. H., Antel J. P., Francis G. S., Williams G., Yong V. W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996 Dec;40(6):853–863. doi: 10.1002/ana.410400607. [DOI] [PubMed] [Google Scholar]
  144. Unemori E. N., Ferrara N., Bauer E. A., Amento E. P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol. 1992 Dec;153(3):557–562. doi: 10.1002/jcp.1041530317. [DOI] [PubMed] [Google Scholar]
  145. Vaalamo M., Leivo T., Saarialho-Kere U. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. Hum Pathol. 1999 Jul;30(7):795–802. doi: 10.1016/s0046-8177(99)90140-5. [DOI] [PubMed] [Google Scholar]
  146. Vaalamo M., Weckroth M., Puolakkainen P., Kere J., Saarinen P., Lauharanta J., Saarialho-Kere U. K. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol. 1996 Jul;135(1):52–59. [PubMed] [Google Scholar]
  147. Vranka J. A., Johnson E., Zhu X., Shepardson A., Alexander J. P., Bradley J. M., Wirtz M. K., Weleber R. G., Klein M. L., Acott T. S. Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid. Curr Eye Res. 1997 Feb;16(2):102–110. doi: 10.1076/ceyr.16.2.102.5086. [DOI] [PubMed] [Google Scholar]
  148. Väisänen A., Kallioinen M., Taskinen P. J., Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol. 1998 Sep;186(1):51–58. doi: 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  149. Väisänen A., Kallioinen M., von Dickhoff K., Laatikainen L., Höyhtyä M., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma? J Pathol. 1999 May;188(1):56–62. doi: 10.1002/(SICI)1096-9896(199905)188:1<56::AID-PATH304>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  150. Wang X., Tromp G., Cole C. W., Verloes A., Sakalihasan N., Yoon S., Kuivaniemi H. Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and 2 (TIMP2) in patients with aneurysms. Matrix Biol. 1999 Apr;18(2):121–124. doi: 10.1016/s0945-053x(99)00008-6. [DOI] [PubMed] [Google Scholar]
  151. Weber B. H., Vogt G., Pruett R. C., Stöhr H., Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet. 1994 Dec;8(4):352–356. doi: 10.1038/ng1294-352. [DOI] [PubMed] [Google Scholar]
  152. Webster L., Chignell A. H., Limb G. A. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res. 1999 Jan;68(1):91–98. doi: 10.1006/exer.1998.0585. [DOI] [PubMed] [Google Scholar]
  153. Werb Z., Vu T. H., Rinkenberger J. L., Coussens L. M. Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS. 1999 Jan;107(1):11–18. doi: 10.1111/j.1699-0463.1999.tb01521.x. [DOI] [PubMed] [Google Scholar]
  154. Westermarck J., Kähäri V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999 May;13(8):781–792. [PubMed] [Google Scholar]
  155. Woessner J. F., Jr Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann N Y Acad Sci. 1999 Jun 30;878:388–403. doi: 10.1111/j.1749-6632.1999.tb07697.x. [DOI] [PubMed] [Google Scholar]
  156. Yang C. S., Khawly J. A., Hainsworth D. P., Chen S. N., Ashton P., Guo H., Jaffe G. J. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998 Jan;116(1):69–77. doi: 10.1001/archopht.116.1.69. [DOI] [PubMed] [Google Scholar]
  157. Zeiss C. J., Acland G. M., Aguirre G. D., RayK TIMP-1 expression is increased in X-linked progressive retinal atrophy despite its exclusion as a candidate gene. Gene. 1998 Dec 28;225(1-2):67–75. doi: 10.1016/s0378-1119(98)00521-6. [DOI] [PubMed] [Google Scholar]
  158. Zhang Y., McCluskey K., Fujii K., Wahl L. M. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol. 1998 Sep 15;161(6):3071–3076. [PubMed] [Google Scholar]
  159. Zucker S. Experimental models to identify antimetastatic drugs: are we there yet? A position paper. Ann N Y Acad Sci. 1999 Jun 30;878:208–211. doi: 10.1111/j.1749-6632.1999.tb07686.x. [DOI] [PubMed] [Google Scholar]
  160. Zucker S., Hymowitz M., Conner C., Zarrabi H. M., Hurewitz A. N., Matrisian L., Boyd D., Nicolson G., Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999 Jun 30;878:212–227. doi: 10.1111/j.1749-6632.1999.tb07687.x. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES